|Bid||21.61 x 800|
|Ask||24.34 x 800|
|Day's range||22.85 - 23.84|
|52-week range||14.21 - 37.75|
|Beta (5Y monthly)||2.58|
|PE ratio (TTM)||6.40|
|Earnings date||14 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||56.31|
SAN DIEGO, December 04, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m.
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.
Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.